SUMMARY In a retrospective study of sweat tests performed on 650 patients, sweat sodium was shown to increase with age in children without cystic fibrosis. The clearest separation of children with and without cystic fibrosis was in the youngest infants, while the highest proportion of repeatedly equivocal results was in the older children. Applying age-related reference ranges did not resolve the equivocal cases without also missing some cases of cystic fibrosis.
A sweat sodium concentration of < 50 mmol/L is widely considered to be a normal result for any prepubertal child. I Values of > 70 mmol/L are consistent with a diagnosis of cystic fibrosis. Early literature on sweat testing concluded that the gradual increase in sweat sodium observed with age did not lead to a diagnostic problem in distinguishing between cystic fibrosis and normal children."
It was our impression that sweat tests on older children were more likely than those on infants to give equivocal results (sweat sodium of 50-70 mmol/L), Consequently we have reviewed our data collected over a four-year period on 650 patients referred for this investigation, to determine whether age-related reference ranges might reduce the number of equivocal results, without increasing the number of false negative results in cystic fibrosis patients.
Methods
The Quantitative Pilocarpine Iontophoresis Test and the Wescor Macroduct sweat testing system are in routine use in this hospital. Sweat testing is restricted to two experienced operators for each method.
QUANTITATIVE PILOCARPINE IONTOPHORESIS TEST
This is based on the method of Gibson and Cooke,' but using a larger (7 em diameter) pilocarpine stimulated area and a longer (60 min) collection time. The larger area makes use of the forearm impossible in small infants and the back Correspondence: Dr J M Kirk.
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is therefore selected as a suitable standard site for all children. Another consequence of the larger collection area is the selection of 200 mg as the minimum acceptable weight for sodium analysis, compared to the 100 mg quoted by Gibson and Cooke.' Samples are eluted into 200 mL of aqueous lithium sulphate solution and analysed for sodium by flame photometry.
WESCOR MACRODUCT SYSTEM
This system is used as described for the Wescor heated cup method.s-' After pilocarpine stimulation sweat is collected from the inner surface of the forearm into a Macroduct collector for approximately 20 min. Five microlitre aliquots of sweat are diluted with 1 mL of aqueous lithium sulphate solution and analysed for sodium by flame photometry. Sweat osmolality is also routinely measured by vapour pressure osmometry. The minimum sweat volume accepted for analysis is 101lL.
PATIENTS
Patients were referred by their paediatrician/ clinician for sweat testing. Typical reasons for the request were: failure to thrive, recurrent respiratory infections, chronic diarrhoea or a family history of cystic fibrosis. 
Results

COMPARISON OF SWEAT TEST METHODS USED
AGE AT FIRST SWEAT TEST REQUEST
Of the 650 patients who had sweat tests performed during the study period, 613 (94'3%) had their age recorded on our request form. Fig. I shows that most sweat test referrals were for babies and toddlers, with 72% of requests being for children less than 3 years old. Only 32 were on patients aged 12 years or over, the oldest patient being 61. diagnosed as having cystic fibrosis, were tested by the quantitative pilocarpine iontophoresis system. Their mean sweat sodium was 32·5 rnmol/L (SO 15,2). The two systems using alternative sites (back and forearm) and different collection times (60 and 20 min), were thus shown to yield equivalent results in our hands (unpaired Student's t-test, NS).
SWEAT YIELD AND AGE
Accurate sweat weights were recorded only for the quantitative pilocarpine iontophoresis tests. Children finally diagnosed as having cystic fibrosis were excluded, as were 3 children who produced < 20 mg of sweat, regarded as iontophoresis failures. Twenty-seven children who produced 21-199 mg of sweat, a yield considered insufficient to give a reliable sodium result, were included.
Overall 6·9% of children less than 12 years old yielded inadequate samples for analysis at their first sweat test, comparing well with the 9·9% reported by Green et 
OUTCOME OF REPEAT SWEAT TESTS
Sixty-nine of the 556 patients not finally diagnosed as having cystic fibrosis gave an equivocal or abnormal result at their first successful sweat test. Table 2 shows the results of repeat sweat tests when they were performed. No child less than one year old gave an abnormal result (> 70 mrnol/L) at any time, and all children in this age group gave normal results ( < 50 mmolL) on retesting. There- l--r-h;:, infants tested). Most of these early diagnoses were due to the rapid referral of two high-risk patient groups: infants with meconium ileus (6 cases) and newborn siblings of known cystic fibrosis children (4 cases). The presentation pattern of older infants and children was quite different. The vast majority of new cystic fibrosis diagnoses were in children referred for sweat testing because of failure to thrive or recurrent respiratory problems.
with a correlation coefficient of 0·11. The slope and correlation coefficient are just significantly different from zero (0,02 < P < 0,05). Fig. 2 shows the distribution of sweat weight for each age group.
DIAGNOSTIC YIELD AND AGE
Thirty-nine patients were diagnosed as having cystic fibrosis, out of 595 whose age was recorded, and who were sweat tested successfully (Table I) . The youngest group, < 4 months old, gave by far the highest diagnostic yield (15 cases from 76 SWEA T SODIUM CON CENTRA TlON AND AGE Thirty-nine patients who were finally diagnosed as having cystic fibrosis were excluded. For all other patients, the sweat sodium obtained at the first test that yielded a sufficient volume was used. For the 532 non-cystic fibrosis children aged under 12 years, the mean sweat sodium was 32·5 mmol/L with a standard deviation of 15·3 mmol/L, Their individual results fitted the regression equation:
Sweat sodium (mmol/L) = 27·1 +2'08 x age in years with a correlation coefficient of 0·34. The slope and correlation coefficient differ from zero with a high degree of significance (P < 0·00 1). Fig. 3 shows the distribution of sweat sodium for each age group for all children. Mean sweat sodium increases steadily with age, from 23·0 mrnol/L in babies of less than 4 months to 41·3 mrnol/L in 6-11 year old children. Two standard deviations above the mean overlaps into the 50-70 mmol/L equivocal range for all children over one year of age.
The 39 patients who were finally diagnosed as having cystic fibrosis had sweat sodium results ranging from 54 to 160 rnmol/L, with the range for each age group shown in Table 1 . For the 35 children aged under 12, the calculated linear regression equation is:
Sweat sodium (mmol/L) = 99·8 -2-4 x age in years with a correlation coefficient of 0·36. The slope and correlation coefficient are just significantly different from zero (0,02 < P < 0'05). All 22 children with cystic fibrosis tested at less than 2 years old gave sweat sodium results greater than 70 mmol/L, However, 6 of 13 children diagnosed as having cystic fibrosis between the ages of 2 and 11 had a sweat sodium result in the 50-70 mmol/L equivocal range at their first sweat test. Repeat sweat test after the proportion of children giving repeated abnormal/equivocal results rose with age. Several children, initially referred 'to exclude cystic fibrosis', had equivocal/abnormal results on a large number of occasions, but were not felt clinically to justify a diagnosis of cystic fibrosis.
Discussion
In common with most laboratories we use literature values to define normal and abnormal sweat sodium ranges. Our definition of less than 50 rnmol/L as normal, 50-70 rnmol/L as equivocal, and greater than 70 mmol/L as abnormal is widely used.
We calculated the mean sweat sodium of all non-cystic fibrosis children under 12 years to be 32·5 mmol/L (SD 15·3 mmol/L), Two standard deviations above the mean, 63·1 mrnol/L, lies near the middle of the equivocal range, and the literature ranges used therefore seemed appropriate.
The action limit for repeating a sweat test, sodium concentration > 50 mrnol/L, was 1·1 SD above our calculated mean, so that we would expect about 12% of children at the upper end of the normal distribution to be referred for repeat testing. In practice, 9·5% of children initially produced a sodium concentration of > 50 mrnol/L, From Table 2 it can be seen that less than 4% of infants under one year old needed repeat testing compared with 19% of6-11 year olds. Our initial impression that older children were more likely to yield equivocal results was therefore confirmed.
If our sweat test referral pattern is typical (Fig.  I) , childhood reference ranges will be heavily biased towards younger age groups, and will be inappropriate for older children as well as for adults, whose increased sweat sodium concentrations relative to childhood reference ranges are well documented.' We have also shown, in contrast to earlier literature, that the increase in sweat sodium observed with age is sufficient to cause diagnostic probems.
Sweat tests on infants are generally thought to be the most problematical. However, our children < 1 year old showed the clearest separation between normal and cystic fibrosis groups. Our data suggest that in areas where neonatal screening is carried out, equivocal results in the confirmatory sweat test should not be a problem. In this situation O'Halloran et a/. s have recently reported cystic fibrosis infants tested at 1-16 weeks of age who had equivocal or even normal sweat sodium levels. Eighty percent of their sweat tests were carried out by 8 weeks of age, whereas we only sweat tested infants aged less than 6 weeks in exceptional circumstances (4 babies) and we are not aware, with a follow up ofl-5 years, of any cystic fibrosis diagnoses having been missed in infants tested during this study.
To reduce equivocal results in older children, we initially considered replacing overall reference ranges with the age-related ranges found for noncystic fibrosis children shown in Fig. 3 . However, using these ranges we would have missed 4 cases of CF presenting between the ages of 2 and 8 years, which is clearly unacceptable. Although the predictive value of a sweat sodium above 50 mrnol/L for cystic fibrosis is lower for older children, the predictive value of a sweat sodium below 70 mmol/L for exclusion of cystic fibrosis also appears to drop with age. The net result is a greater proportion of older children, with and without cystic fibrosis, who have sweat sodium results falling into the equivocal range.
The reason for the increase in sweat sodium with age is probably multifactorial. Hjelm et al" reported no direct correlation between sweat sodium or sweat yield and age, but did find an inverse correlation between sodium and sweat yield. Their results are not directly comparable with ours, as they did not reject low sweat yields for sodium analysis, and it may be that the effect of yield on sodium is more marked in these small samples. We found a correlation between sweat yield and age which just reached statistical significance, but which could not account fully for the increase of sweat sodium with age. Nonetheless, simply repeating the sweat test did resolve a proportion of equivocal cases, some due to a greater sweat yield, and others due to biological and experimental variation.
Administration of fludrocortisone has been used diagnostically to depress sweat sodium concentrations in normal adults," while abnormally high sweat sodium concentrations have been reported in a patient with generalised aldosterone receptor deficiency.'? Plasma aldosterone levels are age-dependent; infants less than a year old have a mean level more than five-fold higher than 5-9 year 01ds. 11 Falling aldosterone levels, by reducing sodium reabsorption in the sweat gland tubule, may contribute to the rise in sweat sodium with age. Laboratories that measure sweat chloride as well as sodium might therefore expect to see a less marked rise in mean sweat chloride levels with age, and an increase in the sodium/choride ratio. There is also a case for carrying out a post-fludrocortisone sweat test in children who have produced two equivocal results, and in whom the diagnosis is not clear on clinical grounds. These possibilities are currently being investigated in a prospective study.
Reliable sweat tests, interpreted according to literature ranges, will refute or confirm a diagnosis of cystic fibrosis in the vast majority of cases. A few, predominantly older, children will give repeatedly equivocal results. It is not possible to classify confidently these children by defining agerelated reference ranges for sweat sodium. Modifications of the standard sweat test need to be evaluated for their ability to resolve these difficult cases.
